Prognostic Significance of CDH1, FN1 and VIM for Early Recurrence in Patients with Colorectal Liver Metastasis After Liver Resection

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Abate D; Global Burden of Disease Cancer C. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.2996
   Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi:10.1136/gutjnl-2015-31091226818619
   PubMed Web of Science ®Google Scholar
• Park JH, Kim JH. Pathologic differential diagnosis of metastatic carcinoma in the liver. Clin Mol Hepatol. 2019;25(1):12–20. doi:10.3350/cmh.2018.006730300991
   PubMed Web of Science ®Google Scholar
• Adam R, Hoti E, Folprecht G, Benson AB. Accomplishments in 2008 in the management of curable metastatic colorectal cancer. Gastrointest Cancer Res. 2009;3(5 Supplement 2):S15–22.20011559
   PubMedGoogle Scholar
• Chow FC-L, Chok KS-H. Colorectal liver metastases: an update on multidisciplinary approach. World J Hepatol. 2019;11(2):150–172. doi:10.4254/wjh.v11.i2.15030820266
   PubMed Web of Science ®Google Scholar
• de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440–448. doi:10.1097/SLA.0b013e3181b4539b19730175
   PubMed Web of Science ®Google Scholar
• Sasaki K, Morioka D, Conci S, et al. The Tumor Burden Score: A New “Metro-ticket” Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors. Ann Surg. 2018;267(1):132–141. doi:10.1097/SLA.000000000000206427763897
   PubMed Web of Science ®Google Scholar
• Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–318. doi:10.1097/00000658-199909000-0000410493478
   PubMed Web of Science ®Google Scholar
• Gomez D, Cameron IC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford). 2010;12(4):227–238. doi:10.1111/j.1477-2574.2010.00158.x20590892
   PubMed Web of Science ®Google Scholar
• Aziz MA, Yousef Z, Saleh AM, Mohammad S, Al Knawy B. Towards personalized medicine of colorectal cancer. Crit Rev Oncol Hematol. 2017;118:70–78. doi:10.1016/j.critrevonc.2017.08.00728917272
   PubMed Web of Science ®Google Scholar
• Cao H, Xu E, Liu H, Wan L, Lai M. Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review. Pathol Res Pract. 2015;211(8):557–569. doi:10.1016/j.prp.2015.05.01026092594
   PubMed Web of Science ®Google Scholar
• Bates RC, Pursell BM, Mercurio AM. Epithelial-mesenchymal transition and colorectal cancer: gaining insights into tumor progression using LIM 1863 cells. Cells Tissues Organs. 2007;185(1–3):29–39. doi:10.1159/00010130017587805
   PubMed Web of Science ®Google Scholar
• Montanari M, Rossetti S, Cavaliere C, et al. Epithelial-mesenchymal transition in prostate cancer: an overview. Oncotarget. 2017;8(21):35376–35389. doi:10.18632/oncotarget.1568628430640
   PubMedGoogle Scholar
• Huang J, Li H, Ren G. Epithelial-mesenchymal transition and drug resistance in breast cancer (Review). Int J Oncol. 2015;47(3):840–848. doi:10.3892/ijo.2015.308426202679
   PubMed Web of Science ®Google Scholar
• Zhu QC, Gao RY, Wu W, Qin HL. Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer. Asian Pac J Cancer Prev. 2013;14(5):2689–2698. doi:10.7314/apjcp.2013.14.5.268923803016
   PubMedGoogle Scholar
• Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014;7(344):re8. doi:10.1126/scisignal.200518925249658
   PubMed Web of Science ®Google Scholar
• Daulagala AC, Bridges MC, E-cadherin Beyond KA. Structure: A Signaling Hub in Colon Homeostasis and Disease. Int J Mol Sci. 2019;20(11):11. doi:10.3390/ijms20112756
   Web of Science ®Google Scholar
• Song Y, Ye M, Zhou J, Wang Z, Targeting ZX. E-cadherin expression with small molecules for digestive cancer treatment. Am J Transl Res. 2019;11(7):3932–3944.31396310
   PubMed Web of Science ®Google Scholar
• Stine JM, Sun Y, Armstrong G, Bowler BE, Briknarova K. Structure and unfolding of the third type III domain from human fibronectin. Biochemistry. 2015;54(44):6724–6733. doi:10.1021/acs.biochem.5b0081826517579
   PubMed Web of Science ®Google Scholar
• Liu CY, Lin HH, Tang MJ, Wang YK. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget. 2015;6(18):15966–15983. doi:10.18632/oncotarget.386225965826
   PubMedGoogle Scholar
• Okugawa Y, Toiyama Y, Inoue Y, et al. Clinical significance of serum soluble E-cadherin in colorectal carcinoma. J Surg Res. 2012;175(2):e67–73. doi:10.1016/j.jss.2011.11.00922277332
   PubMed Web of Science ®Google Scholar
• Yi W, Xiao E, Ding R, Luo P, Yang Y. High expression of fibronectin is associated with poor prognosis, cell proliferation and malignancy via the NF-κB/p53-apoptosis signaling pathway in colorectal cancer. Oncol Rep. 2016;36(6):3145–3153. doi:10.3892/or.2016.517727748871
   PubMed Web of Science ®Google Scholar
• Elzagheid A, et al. E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome. World J Gastroenterol. 2006;12(27):4304–4309. doi:10.3748/wjg.v12.i27.430416865770
   PubMed Web of Science ®Google Scholar
• Jurcic P, Radulovic P, Balja MP, Milosevic M. E-cadherin and NEDD9 expression in primary colorectal cancer, metastatic lymph nodes and liver metastases. Oncol Lett. 2019;17(3):2881–2889. doi:10.3892/ol.2019.991730854064
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao M-J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715. doi:10.1016/j.cell.2008.03.02718485877
   PubMed Web of Science ®Google Scholar
• Repetto O, De Paoli P, De Re V, Canzonieri V, Cannizzaro R. Levels of soluble E-cadherin in breast, gastric, and colorectal cancers. Biomed Res Int. 2014;2014:408047. doi:10.1155/2014/40804725535613
   PubMed Web of Science ®Google Scholar
• Du L, Li J, Lei L, et al. High Vimentin Expression Predicts a Poor Prognosis and Progression in Colorectal Cancer: A Study with Meta-Analysis and TCGA Database. Biomed Res Int. 2018;2018:6387810. doi:10.1155/2018/638781029955607
   PubMed Web of Science ®Google Scholar
• Kida H, Takano Y, Yamamoto K, et al. A single nucleotide polymorphism in fibronectin 1 determines tumor shape in colorectal cancer. Oncol Rep. 2014;32(2):548–552. doi:10.3892/or.2014.325124919860
   PubMed Web of Science ®Google Scholar
• Cepowicz D, Zareba K, Pryczynicz A, et al. Blood serum levels of E-cadherin in patients with colorectal cancer. Prz Gastroenterol. 2017;12(3):186–191. doi:10.5114/pg.2017.7047129123579
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11(3):145–156. doi:10.1038/nrclinonc.2014.524492836
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–437. doi:10.1038/nrc306621562580
   PubMed Web of Science ®Google Scholar
• Nothnick WB, Al-Hendy A, Lue JR. Circulating Micro-RNAs as Diagnostic Biomarkers for Endometriosis: privation and Promise. Journal of Minimally Invasive Gynecology. 2015;22(5):719–726. doi:10.1016/j.jmig.2015.02.02125757811
   PubMed Web of Science ®Google Scholar
• Kanaan Z, Rai SN, Eichenberger MR, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012;256(3):544–551. doi:10.1097/SLA.0b013e318265bd6f22868372
   PubMed Web of Science ®Google Scholar
• Gao S, Zhao Z-Y, Wu R, Zhang Y, Zhang Z-Y. Prognostic value of microRNAs in colorectal cancer: a meta-analysis. Cancer Manag Res. 2018;10:907–929. doi:10.2147/CMAR.S15749329750053
   PubMed Web of Science ®Google Scholar
• Niknami Z, Eslamifar A, Emamirazavi A, Ebrahimi A, Shirkoohi R. The association of vimentin and fibronectin gene expression with epithelial-mesenchymal transition and tumor malignancy in colorectal carcinoma. EXCLI J. 2017;16:1009–1017. doi:10.17179/excli2017-48128900381
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Brennan JP, Slavin JL. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res. 2006;66(23):11271–11278. doi:10.1158/0008-5472.CAN-06-204417145872
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890. doi:10.1016/j.cell.2009.11.00719945376
   PubMed Web of Science ®Google Scholar
• Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Migrating cancer stem cells — an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005;5(9):744–749. doi:10.1038/nrc169416148886
   PubMed Web of Science ®Google Scholar
• Truant SC, Gouyer VP, Leteurtre EA, Zerimech F, Huet GM, Pruvot F-R-R. E-Cadherin and β-Catenin mRNA Levels Throughout Colon Cancer Progression. J Surg Res. 2008;150(2):212–218. doi:10.1016/j.jss.2007.12.80018316097
   PubMed Web of Science ®Google Scholar
• Ionescu C, Braicu C, Chiorean R, et al. TIMP-1 expression in human colorectal cancer is associated with SMAD3 gene expression levels: a pilot study. J Gastrointestin Liver Dis. 2014;23(4):413–418. doi:10.15403/jgld.2014.1121.234.smad25532000
   PubMed Web of Science ®Google Scholar
• Ceausu AR, Ciolofan A, Cimpean AM, Magheti A, Mederle O, The Mesenchymal-Epithelial RM. Epithelial-Mesenchymal Cellular Plasticity of Liver Metastases with Digestive Origin. Anticancer Res. 2018;38(2):811–816. doi:10.21873/anticanres.1228829374706
   PubMed Web of Science ®Google Scholar
• Saito N, Nishimura H, Kameoka S. Clinical significance of fibronectin expression in colorectal cancer. Mol Med Rep. 2008;1(1):77–81.21479381
   PubMed Web of Science ®Google Scholar
• Nanashima A, Yamaguchi H, Sawai T, et al. Expression of adhesion molecules in hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol. 1999;14(10):1004–1009. doi:10.1046/j.1440-1746.1999.01991.x10530497
   PubMed Web of Science ®Google Scholar
• Nanashima A, Yamaguchi H, Sawai T, et al. Prognostic factors in hepatic metastases of colorectal carcinoma: immunohistochemical analysis of tumor biological factors. Dig Dis Sci. 2001;46(8):1623–1628. doi:10.1023/a:101068081595411508659
   PubMed Web of Science ®Google Scholar